CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - nature.com
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
CAR-T cell therapy in hematological malignancies: current opportunities and challenges
X Zhang, L Zhu, H Zhang, S Chen, Y Xiao - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …
treatment, and it has achieved unprecedented success in hematological malignancies …
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
INTRODUCTION More than 50% of patients treated with chimeric antigen receptor (CAR)–T
cells for B cell malignancies develop progressive disease after CAR therapy, and these …
cells for B cell malignancies develop progressive disease after CAR therapy, and these …
Proximity-based modalities for biology and medicine
Molecular proximity orchestrates biological function, and blocking existing proximities is an
established therapeutic strategy. By contrast, strengthening or creating neoproximity with …
established therapeutic strategy. By contrast, strengthening or creating neoproximity with …
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
Regulatable CAR platforms could circumvent toxicities associated with CAR-T therapy, but
existing systems have shortcomings including leakiness and attenuated activity. Here, we …
existing systems have shortcomings including leakiness and attenuated activity. Here, we …
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
X Xiao, S Huang, S Chen, Y Wang, Q Sun… - Journal of Experimental & …, 2021 - Springer
Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …
The future of engineered immune cell therapies
Immune cells are being engineered to recognize and respond to disease states, acting as a
“living drug” when transferred into patients. Therapies based on engineered immune cells …
“living drug” when transferred into patients. Therapies based on engineered immune cells …
From thalidomide to rational molecular glue design for targeted protein degradation
Thalidomide and its derivatives are powerful cancer therapeutics that are among the best-
understood molecular glue degraders (MGDs). These drugs selectively reprogram the E3 …
understood molecular glue degraders (MGDs). These drugs selectively reprogram the E3 …
[HTML][HTML] Prediction of prime editing insertion efficiencies using sequence features and DNA repair determinants
Most short sequences can be precisely written into a selected genomic target using prime
editing; however, it remains unclear what factors govern insertion. We design a library of …
editing; however, it remains unclear what factors govern insertion. We design a library of …